TRex Bio Prices $117 Million IPO to Fund Immune Drug Pipeline
TRex Bio has priced a $117 million IPO to fund its immune drug programs, BioPharma Dive reports, giving the biotech capital to advance clinical-stage candidates.
Topic
Biotechnology
Topic
Biotechnology
Sensible Biotechnologies Raises $47 Million With In-Q-Tel Backing
Sensible Biotechnologies secured $47 million, with In-Q-Tel and OTB Ventures in a Series A plus up to $20 million from Slovakia a…
Cyriac Roeding: U.S. Risks Losing Biotech Lead — Not Over Regulation
Investor Cyriac Roeding warns the U.S. risks losing biotech leadership, arguing the real threat is not regulation despite years o…